NFCR Congratulates GCAR on its New Partnership & GBM AGILE Expansion
The National Foundation for Cancer Research (NFCR) and CEO Sujuan Ba, Ph.D., congratulate the Global Coalition for Adaptive Research (GCAR) for their continued commitment to expanding options for cancer patients and perseverance in the fight against difficult-to-treat cancers.
Recently, GCAR announced its strategic partnership with the Pancreatic Cancer Action Network (PANCAN) to accelerate treatment options for pancreatic cancer patients. In collaboration, GCAR and PANCAN will launch the next phase of their clinical trial.
Pancreatic cancer is one of the few cancers for which survival has not improved substantially in over 40 years. It has proved difficult to diagnose in the early stages when cancer is most treatable. Consequently, the overall five-year survival rate for pancreatic cancer is just 12%.
Pancreatic patients and their families deserve better.
Dr. Ba is one of the few individuals who has been a part of GBM AGILE from the beginning, fighting for progress for cancer patients. Dr. Ba co-founded GBM AGILE, the innovative, paradigm-shifting clinical trial accelerating how we review and approve life-saving cancer treatments for the most difficult-to-treat cancers, such as glioblastoma (GBM). Part of the founding vision of GCAR was to expand the adaptive clinical trial approach beyond GBM. GCAR’s alliance with PANCAN demonstrates they are taking the necessary steps to achieve this goal and provide great hope for cancer patients.
From the Press Release:
“GCAR is excited to collaborate with PanCAN to launch this innovative and groundbreaking effort, continuing to work with the clinicians, patient community and industry to move forward the vision to improve treatment options for patients,” said Dr. Meredith Buxton, CEO & President, GCAR.
NFCR extends our kudos to both GCAR and PANCAN for their commitment to improving cancer survivorship!
Cures for cancer are coming! Be a part of the movment to Make Cures Possible.
